( Last Updated : August 4, 2021)
Generic Name:
Project Status:
Therapeutic Area:
Hyperkalemia, adults (chronic kidney disease)
Otsuka Canada Pharmaceuticals Inc.
Brand Name:
Project Line:
Reimbursement Review
Project Number:
NOC Status at Filing:
Post NOC


Manufacturer Requested Reimbursement Criteria1:
For the treatment of hyperkalemia in adults with CKD 3-4 on RAASi therapy.
Submission Type:
Fee Schedule:
Schedule A
For the treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m).
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openOctober 02, 2020
Call for patient/clinician input closedNovember 23, 2020

- Patient input submission received from the The Kidney Foundation of Canada

Submission receivedOctober 30, 2020
Submission acceptedNovember 13, 2020
Review initiatedNovember 16, 2020
Draft CADTH review report(s) provided to sponsor for commentFebruary 25, 2021
Deadline for sponsors commentsMarch 08, 2021
CADTH responses on draft review report(s) provided to sponsorApril 09, 2021
Expert committee meeting (initial)April 21, 2021
Draft recommendation issued to sponsorMay 03, 2021
Draft recommendation posted for stakeholder feedbackMay 13, 2021
End of feedback periodMay 28, 2021
Final recommendation issued to sponsor and drug plansJune 08, 2021
Final recommendation postedJune 24, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)June 22, 2021
CADTH review report(s) postedAugust 04, 2021